The newest variant of concern Omicron (B.1.1.529) contains over 30 reported mutations in the S gene, with implications for receptor binding and transmissibility as well as antibody escape and immune evasion. It is therefore important to show that the diagnostic accuracy of SARS-CoV-2 assays is not affected. After detailed in silico analysis of the available sequences in variant databases such as GISAID (as at 10/12/2021), DiagCor Life Science is happy to report that none of the mutations associated with the Omicron variant affects our GenoScreenTM SARS-CoV-2 RT-qPCR Assay. Clinical laboratories using this assay can proceed with confidence for their testing operations.
Headquartered in Hong Kong with ISO 13485 accredited Quality Management System, DiagCor has been dedicated solely to molecular diagnostics (MDx) since 2006. The global leader in flow-through hybridization technology, the company offers a range of products, solutions and services related to RNA and DNA analysis. As well as providing MDx laboratory services to Asia Pacific practitioners, DiagCor develops and manufactures MDx products and solutions, and offers MDx medical translation services and MDx consulting.
DiagCor Life Science